

## 5. Ablauf für Autor/innen

Der betreffende Autor/in erhält nach der Annahme eine E-Mail mit einem eindeutigen Link, über den er die Autorenreise abschließen und die Veröffentlichungsoptionen auswählen kann

Der Autor/die Autorin klickt auf das Formular „Complete the Rights and Access form“

Corresponding author [redacted]

E-mail address [redacted]

Journal International Journal of Pharmaceutics

Article number 121624

Our reference IJP\_121624

PII S0378-5173(22)00179-X

Welcome [redacted]

To help us finalize the publication of your article please complete the publishing form(s) below.

**Note:** you will receive a confirmation e-mail after completing each form.

[Information you may need to provide to complete the forms](#)

### Rights and Access

[Complete the rights and access form >](#)

### Help and Support

[How you can share your article](#)

[Author rights information](#)

[A guide to publishing Open Access](#)

## Rights and Access



**Der korrespondierende Autor/in wählt seine/ihre Angaben zur Zugehörigkeit aus, die wir verwenden, um die Autor/innen zu identifizieren und sie dem DEAL-Vertrag zuzuordnen.**

**Bitte beachten Sie, dass der Autor/in diese Informationen bereits bei der Einreichung angegeben hat; sie sind bereits vorausgefüllt.**

Corresponding author  
E-mail address  
Journal  
Article number  
Our reference  
PII

### Corresponding Author's Organization ⓘ

Please enter the corresponding author's organization. We use this information so we can offer tailored publishing options and a personalized article publishing charge for Gold open access when applicable.


**Hint:** start your search using your main organization name (e.g. University of Manchester) as this will return the most results from which to select the most appropriate option. If you're unable to find your specific department, then selecting your main organization is sufficient. For more tips on searching for an organization please visit our [Support Center](#).

#### Organization name\*

max-plan|

- Max Planck Society  
München, DE
- Max-Planck-Gesellschaft  
München, DE
- Max-Planck-Institut für Limnologie  
München, DE
- Max-Planck Institute of Experimental Endocrinology  
Göttingen, DE
- Max-Planck-Institut für Experimentelle Medizin  
Göttingen, DE
- Max-Planck-Institut für Multidisziplinäre Naturwissenschaften  
Göttingen, DE
- Max-Planck-Institut für experimentelle Medizin

Save and Continue >



Der korrespondierende Autor/in fügt auch die Angaben zur Zugehörigkeit der Mitautor/innen hinzu

▼

Were there any co-authors for this article?

Yes


No

### Add Co-author Details ⓘ

Please provide details for all co-authors. We use this information so we can offer tailored publishing options and a personalized article publishing charge for Gold open access when applicable.

**Hint:** start the organization search using the main organization name (e.g. University of Manchester) as this will return the most results from which to select the most appropriate option. If you're unable to find the specific department, then selecting the main organization is sufficient. For more tips on searching for an organization please visit our [Support Center](#).

First name or initial*	Last name*	🗑️
<input type="text" value="John"/>	<input type="text" value="Head"/>	
Organization name*	<input type="text" value="KU Leuven"/>	
Or use recently selected organization		
<input type="text" value="Name of the author (optional)"/>		
<a href="#">+ Add another co-author</a>		



Der Autor, die Autorin kann die Angaben zum Förderer hinzufügen. Der Förderer kann die angeschlossene Einrichtung oder eine andere sein. In diesem Fall ist es Milliman Inc

Review Order and Confirmation questions using a different role permission model

Did the research in this article receive funding?

- Yes
- No

## Funder Details ⓘ

Determine the best publishing options for your article. Please include the details about any funding received outside of your primary affiliations. If providing details for two or more organizations, please list the organization(s) that provided the most funding first.

For tips on searching for an organization please visit our [Support Center](#)

Organization name\*

Milliman Inc



Grant/Contract numbers\*

GT123



+ Add grant/contract number

+ Add another organization

Previous

Save and Continue >

Based on information you have provided, your publishing option is shown below

## Gold Open Access

Publish as an Open Access article

Because you are affiliated with (institution), your open access publishing fee is covered under the agreement between the [DEAL Consortium and Elsevier](#).

- Only submitting corresponding authors are eligible, and your affiliation will be verified by your institution above
- Please make sure this institution is stated as your affiliation in your manuscript
- You will not be invoiced by Elsevier or DEAL but some institutions may pass on some or all of the publishing fees to authors. You may wish to check your institutional policy with your local library or OA officer

For more information visit [DEAL Consortium page](#).

Please contact [DEAL-Elsevier Publishing](#) if you do not wish to publish open access.

### DEAL Agreement Fee

Price

EUR 2,550.00

DEAL Agreement Coverage



- 2,550.00

**To pay (on validation)**



**0.00**


If your institution cannot verify your affiliation, you will receive a full price invoice for EUR 5,340.00 (ex. VAT), but you will still be able to choose not to publish OA free of charge if you contact [Researcher Support](#) within 2 weeks of receiving an invoice.

[DEAL and Elsevier Agreement](#)

Previous

Save and Continue >

Veröffentlichungsmöglichkeiten in einer Hybridzeitschrift



Veröffentlichungs  
möglichkeiten in  
einer OpenAccess  
Zeitschrift

[Redacted area]

Based on information you have provided, your publishing option is shown below

## Gold Open Access

Publish as an Open Access article

Because you are affiliated with (institution), your open access publishing fee is covered under the agreement between the [DEAL Consortium and Elsevier](#).

- Only submitting corresponding authors are eligible, and your affiliation will be verified by your institution above
- Please make sure this institution is stated as your affiliation in your manuscript
- You will not be invoiced by Elsevier or DEAL but some institutions may pass on some or all of the publishing fees to authors. You may wish to check your institutional policy with your local library or OA officer


For more information visit [DEAL Consortium page](#).

<b>Article Publishing Charge (APC)</b>	
	Price
	EUR 3,000.00
	DEAL Agreement Coverage
	- 3,000.00
<hr/>	
	<b>To pay (on validation)</b>
	<b>0.00</b>
If your institution cannot confirm your affiliation, you will receive a full price invoice for EUR 3,000.00 (ex. VAT).	
<a href="#">DEAL and Elsevier Agreement</a>	

Previous

Save and Continue >

## Rights and Access



- Das System zeigt dem Autor/ der Autorin die CC-Lizenzoptionen an
- CC BY-Lizenz ist vorausgewählt

## Select your user license

Please select your license. If you need to comply with a mandated license and the mandated license is not listed below, please visit our [Support Hub](#) for additional help.

 CC BY 4.0

A license to permit readers to share and adapt your article for any purpose, even commercially.

[Read more about CC BY 4.0](#)


 CC BY-NC-ND 4.0

A license to permit readers to share all or part of your article in any medium or format for non-commercial purposes. Permission from Elsevier is required for the distribution of derivative versions of the article or for commercial use.

[Read more about CC BY-NC-ND 4.0](#)

[Previous](#)[Save and Continue >](#)





## Der Autor/die Autorin wählt die Rechte aus

How best to describe your work? [View all options](#)

Elsevier B.V.

### Select Your Status

I am the sole author of the manuscript

I am one author signing on behalf of all co-authors of the manuscript

Please indicate which of the below applies to you:

We are all US Government employees and the Article is public domain and therefore the 'License of publishing rights' clause does not apply

I am a US Government employee but some of my co-authors are not

I am not a US Government employee but some of my co-authors are

The work was performed by contractors of the US Government under contract number:

Contract Number\*

All or some of the authors are UK, Canadian or Australian Government employees and Crown Copyright is asserted

Some of the authors are employees of the UK, Canadian or Australian Government but Crown Copyright is not asserted

None of the above

I am signing as an authorized representative and on behalf of my employer

### Signed on Behalf of Corresponding Author

Please complete this section if you are not the corresponding author as listed above. A copy of the agreement will be sent to you and the corresponding author.


I am signing on behalf of the corresponding author

Name, job title and company (if employer representative)\*

E-mail address\*

Previous

Save and Continue >



Elsevier B.V.

Elsevier B.V.

## Your Status

- I am one author signing on behalf of all co-authors of the manuscript

## License of Publishing Rights

I hereby grant to Elsevier B.V. an exclusive publishing and distribution license in the manuscript identified above and any tables, illustrations or other material submitted for publication as part of the manuscript (the "Article") in print, electronic and all other media (whether now known or later developed), in any form, in all languages, throughout the world, for the full term of copyright, and the right to license others to do the same, effective when the Article is accepted for publication. This license includes the right to enforce the rights granted hereunder against third parties.

## Supplemental Materials

"Supplemental Materials" shall mean materials published as a supplemental part of the Article, including but not limited to graphical, illustrative, video and audio material.

With respect to any Supplemental Materials that I submit, Elsevier B.V. shall have a perpetual worldwide non-exclusive right and license to publish, extract, reformat, adapt, build upon, index, redistribute, link to and otherwise use all or any part of the Supplemental Materials, in all forms and media (whether now known or later developed) and permit others to do so. The publisher shall apply the same end user license to the Supplemental Materials as to the Article where it publishes the Supplemental Materials with the Article in the journal on its online platforms on an Open Access basis.

## Research Data

"Research Data" shall mean the result of observations or experimentation that validate research findings and that are published separate to the Article, which can include but are not limited to raw data, processed data, software, algorithms, protocols, and methods.

Das System präsentiert dem Autor/der Autorin die Veröffentlichungsvereinbarung für die Zeitschriftenlizenz

For further information see the publishing ethics page at <https://www.elsevier.com/about/our-business/policies/publishing-ethics> and the journal home page. For further information on sanctions, see <https://www.elsevier.com/about/our-business/policies/trade-sanctions>

#### Author representations

- The Article I have submitted to the journal for review is original, has been written by the stated authors and has not been previously published.
- The Article was not submitted for review to another journal while under review by this journal and will not be submitted to any other journal.
- The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libellous or other unlawful matter.
- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials.
- Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses.
- If I and/or any of my co-authors reside in Iran, Cuba, or Syria, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.
- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher's policies relating to the use of such images or personal information. See <https://www.elsevier.com/about/our-business/policies/patient-consent> for further information.
- Any software contained in the Supplemental Materials is free from viruses, contaminants or worms.
- If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

#### Governing Law and Jurisdiction

This License Agreement will be governed by and construed in accordance with the laws of the country or state of International Federation of Automatic Control ("the Governing State"), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

For information on the publisher's copyright and access policies, please see <http://www.elsevier.com/copyright>.

I have read and agree to the terms of the License Agreement.

17 December 2021

T-copyright license-v5/2017

Previous

Accept Agreement >

Der Autor/ die Autorin erklärt  
sich mit dem Journal  
License Publishing  
Agreement einverstanden

1

Corresponding  
Author

2

Co-Author

3

Research  
Funders

4

Society  
Membership

5

Publishing  
Options

6

Licenses

7

Rights

8

Publishing  
Agreement

9

Review Order

10

Confirmation

Sobald der Autor/ die Autorin auf "Fertigstellen" klickt:

Der **korrespondierende Autor/in** und die **Co-Autor/innen** erhalten eine Kopie der **Zusammenfassung per E-Mail**.

Der Bibliothekar/in/Administrator/in der Einrichtung erhält innerhalb von **48 Stunden** eine Benachrichtigung zur **Bestätigung** und hat dann **3 Wochen** Zeit, den Antrag zu bestätigen.

Wenn der Bibliothekar/in/Administrator/in den Antrag **genehmigt**, erhält der Autor/in die **volle APC-Leistung**

**Lehnt** der Bibliothekar/in/Administrator/in den Antrag **ab**, erhält der Autor/in die Rechnung über den **vollen Preis**.



## Review Order

### Research Funders

Milliman Inc  
Grant numbers: GT123

### Publishing Option

Gold Open Access

### User License

CC BY 4.0

### Publishing Agreement

- I am one author signing on behalf of all co-authors of the manuscript

I may share my final published article widely in accordance with the [user License](#) that I have selected.  
Further details on [Elsevier Sharing Policy here](#).

25 September 2023

Previous

## Total payment due

Price (excluding taxes)

EUR 2,550.00

DEAL Agreement Coverage

- 2,550.00



To pay (on validation)

0.00



If your institution cannot verify your affiliation, you will receive a full price invoice for EUR 5,340.00 (ex. VAT), but you will still be able to choose not to publish OA free of charge if you contact [Researcher Support](#) within 2 weeks of receiving an invoice.

[DEAL and Elsevier Agreement](#)

Finish >